NMRD - Nemaura Medical Inc (NASDAQ: NMRD) Has announced the development of the world's first non-invasive wearable lactic acid monito

Nemaura Medical Inc (NASDAQ: NMRD) Has announced the development of the world's first non-invasive wearable lactic acid monitor. April 23, 2019 -- 

-- Further, we are pleased to say that the company is no longer over reliant on its glucose monitoring system for revenue. Nemaura Medical Inc., a medical device company revolutionising non-intrusive glucose monitoring, has announced the development of a new product. The much coveted wearable real time monitoring device which has been developed from its flagship product SugarBeat by revamping the original design to monitor the user's lactic acid levels, results will be instantly transmitted directly to the user's smartphones. Nemaura is the world's first company in the non-invasive lactic acid monitoring market and is poised to establish itself as a world leader in personal fitness monitoring devices. Why is this important? Nemaura is the first company in this arena(1) and the current market size for wearable's is currently over $19.6b and is estimated to exceed $65b by 2023(1). The new device and app tell you how hard your body is working in real time and further show real time recovery by monitoring lactic acid levels. As the device is a consumer product, it does not require regulatory approval(2) in any world market and can potentially get to market in months dependant on the distribution model the company selects. The product has multiple applications and advantages in industries such as; 1. Gym, sports, hiking & at home. 2. At work in many industries. 3. Trucking industry to ensure drivers are not over working. 4. Military & Law enforcement. 5. General wellbeing & many more. 6. Clothing and apparel integration. The company is still on track for its glucose monitoring device development timeline and we will advise the market of any updates. This stock is poised for a long a prosperous run and may even end up north of $15.00. There is no ceiling or limitation to the market size for this product.

References 1. 4/19/2019 8K Filings NMRD 2. FDA.GOV (General Wellness: Policy for Low Risk Devices)